Summary & Overview
HCPCS M1185: Documentation of Immune Checkpoint Inhibitor/Corticosteroid Management Not Performed
HCPCS Level II code M1185 represents documentation that immune checkpoint inhibitor therapy was not held and/or corticosteroids or immunosuppressants were not prescribed or administered, with no reason provided. This code signals a gap in the clinical documentation of immunotherapy management and is relevant to oncology practices, infusion centers, and payers monitoring appropriate handling of immune-related adverse events. Nationally, use of this code affects quality reporting, prior authorization review, and audit risk for cancer treatment episodes.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines expected use cases for M1185, common sites of service, and implications for clinical documentation quality. Readers will find benchmarks for utilization where available, discussion of policy and coding guidance, and clinical context around immune checkpoint inhibitor management — including when therapy might be held or when corticosteroids/immunosuppressants are indicated.
The report does not provide state-specific guidance; it summarizes national implications for documentation practices, coding accuracy, and payer review processes. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code M1185 documents that immune checkpoint inhibitor therapy was not held and/or corticosteroids or immunosuppressants were not prescribed or administered, with no reason provided for these actions. The code captures missing documentation related to management of immune-related adverse events or therapy interruptions during cancer immunotherapy.
Service type: Documentation / Clinical administrative item related to oncology medication management
Typical site of service: Outpatient oncology clinics, infusion centers, and other ambulatory care settings where immune checkpoint inhibitor therapy is administered
Clinical & Coding Specifications
Clinical Context
A patient receiving an immune checkpoint inhibitor (ICI) such as pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, or cemiplimab presents for routine oncology infusion follow-up. During the visit the clinician documents that ICI therapy was not withheld and that corticosteroids or other immunosuppressants were not prescribed or administered, but no reason for these actions is recorded. Typical workflow: the oncology nurse and infusion pharmacist verify vitals, labs, and symptom screening for immune-related adverse events (irAEs); the oncologist performs an evaluation and documents decision-making in the medical record. The treatment is continued as scheduled; orders are placed for the next infusion and routine monitoring. Typical site of service for this documentation is an outpatient oncology infusion center or hospital outpatient department where systemic anticancer therapy is delivered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when documentation supports substantially greater effort or time for evaluation related to complex ICI management documentation. |
23 | Unusual anesthesia |